Why Kim Kardashian's Instagram Post Was In Violation of FDA Rules

Kim Kardashian may be a marketing genius who has built one of the world’s most successful celebrity brands -- but when the Food and Drug Administration came knocking at her door, she knew to listen. Kardashian, who frequently posts endorsements to social media for brands she partners with, recently put up an Instagram post gushing about morning sickness drug Diclegis, as part of a formal partnership with parent company Duchesnay. This led to a letter from the FDA to Duchesnay that deemed her post misleading and requested that she post another one clarifying the risks associated with the drug.

On Aug 30, Kardashian took to Instagram to do just that -- and this time, her post featured a lengthy disclaimer. It turns out that Kardashian and Duchesnay, as a result of their partnership, fell afoul of strict FDA rules regarding what companies can and cannot say about prescription drugs via social media. Namely, she did not make mandatory statements about the drug's side effects and comply with the same rules that require spoken disclaimers at the close of television commercials for prescription drugs.